Evidence map›Paper›PMID 35233783›Full record

ArticleJournal of medical virology2022

Active surveillance and early detection of community transmission of SARS-CoV-2 Mu variant (B.1.621) in the Brazilian Amazon.

Gabriella S Oliveira, Luciana Silva-Flannery, Juliana F Silva, Charlene Siza, Roberto J Esteves, Barbara J Marston, Juliette Morgan, Mateusz Plucinski, Tárcio P Roca, Ana M P Silva and 6 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 2 institutions in 2 countries.

Gabriella S OliveiraLaboratório de Virologia Molecular, Fundação Oswaldo Cruz, Fiocruz, Rondônia, Brazil.
Luciana Silva-FlanneryCOVID-19 Response - Internation Task Force, Centers for Diseases Control and Prevention (CDC), Atlanta, Georgia, USA.ORCID 0000-0002-5762-8451
Juliana F SilvaCOVID-19 Response - Internation Task Force, Centers for Diseases Control and Prevention (CDC), Atlanta, Georgia, USA.
Charlene SizaCOVID-19 Response - Internation Task Force, Centers for Diseases Control and Prevention (CDC), Atlanta, Georgia, USA.
Roberto J EstevesSouth America Regional Office, Centers for Diseases Control and Prevention (CDC), Brasília, Brazil.
Barbara J MarstonCOVID-19 Response - Internation Task Force, Centers for Diseases Control and Prevention (CDC), Atlanta, Georgia, USA.
Juliette MorganSouth America Regional Office, Centers for Diseases Control and Prevention (CDC), Brasília, Brazil.
Mateusz PlucinskiCOVID-19 Response - Internation Task Force, Centers for Diseases Control and Prevention (CDC), Atlanta, Georgia, USA.
Tárcio P RocaLaboratório de Virologia Molecular, Fundação Oswaldo Cruz, Fiocruz, Rondônia, Brazil.
Ana M P SilvaLaboratório de Virologia Molecular, Fundação Oswaldo Cruz, Fiocruz, Rondônia, Brazil.
Soraya S PereiraLaboratório de Engenharia de Anticorpos, Fiocruz, Rondônia, Brazil.
Juan M V SalcedoLaboratório de Virologia Molecular, Fundação Oswaldo Cruz, Fiocruz, Rondônia, Brazil.
Dhelio B PereiraCentro de Pesquisa em Medicina Tropical, CEPEM, Porto Velho, Rondônia, Brazil.
Felipe G NavecaLaboratório de Ecologia de Doenças Transmissíveis na Amazônia, Instituto Leônidas e Maria Deane, Fiocruz, Amazonas, Brazil.
Deusilene S Vieira Dall'AcquaLaboratório de Virologia Molecular, Fundação Oswaldo Cruz, Fiocruz, Rondônia, Brazil.
Brazil Investigation Team
Fundação Oswaldo Cruz · BRCenters for Disease Control and Prevention · US

Funding

Centers for Disease Control and Prevention (CDC)
6 · The paper itself

Abstract

Through active surveillance and contact tracing from outpatients, we aimed to identify and characterize SARS-CoV-2 variants circulating in Porto Velho-Rondônia, a city in the Brazilian Amazon. As part of a prospective cohort, we gathered information from 2,506 individuals among COVID-19 patients and household contacts. Epidemiological data, nasopharyngeal swabs, and blood samples were collected from all participants. Nasopharyngeal swabs were tested for antigen rapid diagnostic test and reverse transcription-polymerase chain reaction (RT-PCR) followed by genomic sequencing. Blood samples underwent ELISA testing for IgA, IgG, and IgM antibody levels. From 757 specimens sequenced, three were identified as Mu variant, none of the individuals carrying this variant had a travel history in the previous 15 days before diagnosis. One case was asymptomatic and two presented mild symptoms. Two infected individuals from different households caring viruses with additional amino acid substitutions ORF7a P45L and ORF1a T1055A compared to the Mu virus reference sequence. One patient presented IgG levels. Our results highlight that genomic surveillance for SARS-CoV-2 variants can assist in detecting the emergency of SARS-CoV-2 variants in the community, before its identification in other parts of the country.

Indexed as

COVID-19SARS-CoV-2BrazilHumansImmunoglobulin GProspective StudiesWatchful WaitingImmunoglobulin GActive surveillanceBrazilian AmazonMu variantSARS-CoV-2

Identifiers

PMID35233783
PMCPMC9088640
OpenAlexW4214923966

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.